Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” and “Best in Class” anti-inflammatory and cancer therapy drugs in addition to achieving other business platform such as functional cosmeceutical, contrast agents for cancer diagnostics, and theranostics.
The world’s First PEGylated Bilirubin platform Technology
-
Founder & CEO
Myung L. Kim, Ph.D
-
Professor
SangYong Jon
Bilirubin: Byproduct of heme metabolism
Developmental strategy
Target indication with BRNP
Acute inflammatory disease with IV or infusion treatment
- Organ transplantation
- Buerger’s disease
- Ischemic heart disease
- Ischemic stroke
Chronic inflammatory disease with SC or oral administration
- Inflammatory bowl disease
- Rheumatoid arthritis
Target indication with BRNP
Cancer drug carrier
- Hepatocellular carcinoma with Nexavar @ BRNP
- Cytotoxic cancer drugs: Doxorubicin, paxclitaxel
Peptide drug conjugated BRNP
One Platform Target All with Pegylated bilirubin
We are the first to case a New Technology that Converted Bilirubin to a New Drug.
OPTA Platform
3 Areas of PEGyated Bilirubin Applications
01Inflammation
02Cancer
03Imaging Contrast Agent
- Patent #1
- Bilirubin nanoparticle, use thereof, and preparation method therefor
[Filing Number: 10-2013-0165718(2013.12.27), KR, PCT, US, EP] - Patent #2
- Engineering of various metal coordinated complexes with PEGylated bilirubin and its diverse application
[Filing Number: 10-2017-0059597(2017.05.12), KR, PCT, US, EP] - Patent #3
- Bilirubin Derivatives Based Ultrasound Contrast Agent For Theranostics
[Filing Number: 10-2018-0014160, KR, PCT, US, EP]